Levamisole is ineffective in the treatment of amyotrophic lateral sclerosis.
Fifty-nine patients with amyotrophic lateral sclerosis participated in a 12-month, double-blind crossover trial. The patients were given either levamisole 150 mg or placebo in identical tablets once a week orally, and a rating of neurologic signs and symptoms was recorded on monthly visits. The patients were crossed over at 6 months. Levamisole had no effect on the rate of score decline in the 20 patients who completed the trial.
D000328:Adult; D000368:Aged; D000690:Amyotrophic Lateral Sclerosis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007978:Levamisole / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010919:Placebos
D010919:Placebos; D007978:Levamisole